"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.015(6.82%) |
Mkt cap ! $370.1M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.5¢ | 21.5¢ | $945.7K | 4.195M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 369000 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 820599 | 14 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.015 ( 8.05 %) |
||||
| Open | High | Low | Volume | ||
| 21.8¢ | 23.5¢ | 21.5¢ | 1080802 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| BOT (ASX) Chart |